| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Unidad de Investigacion, Servicio de Nefrologia, Hospital Universitario Reina Sofia, Cordoba, Spain
2 NPS Pharmaceuticals, Inc., Toronto, Ontario, Canada
3 Amgen Inc., Thousand Oaks, CA, USA
* To whom correspondence should be addressed. E-mail: juanm.rodriguez.sspa{at}juntadeandalucia.es.
Serum calcium levels are regulated by the action of parathyroid hormone (PTH). Major drivers of PTH hypersecretion and parathyroid cell proliferation are the hypocalcemia and hyperphosphatemia that develop in chronic kidney disease patients with secondary hyperparathyroidism (SHPT) as a result of low calcitriol levels and decreased kidney function. Increased PTH production in response to systemic hypocalcemia is mediated by the calcium-sensing receptor (CaR). Furthermore, as SHPT progresses, reduced expression of CaRs and vitamin D receptors (VDRs) in hyperplastic parathyroid glands may limit the ability of calcium and calcitriol to regulate PTH secretion. Current treatment for SHPT includes the administration of vitamin D sterols and phosphate binders. Treatment with vitamin D is initially effective, but efficacy often wanes with further disease progression. The actions of vitamin D sterols are undermined by reduced expression of VDRs in the parathyroid gland. Furthermore, the calcemic and phosphatemic actions of vitamin D mean that it has the potential to exacerbate abnormal mineral metabolism, resulting in the formation of vascular calcifications. Effective new treatments for SHPT that have a positive impact on mineral metabolism are clearly needed. Recent research shows that drugs that selectively target the CaR, calcimimetics, have the potential to meet these requirements.
This article has been cited by other articles:
|
|
 |
|
  V. Lavi-Moshayoff, J. Silver, and T. Naveh-Many Human PTH gene regulation in vivo using transgenic mice Am J Physiol Renal Physiol, September 1, 2009; 297(3): F713 - F719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nechama, I. Z. Ben-Dov, J. Silver, and T. Naveh-Many Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD Am J Physiol Renal Physiol, April 1, 2009; 296(4): F795 - F800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-u. Alam, J. P. Kirton, F. L. Wilkinson, E. Towers, S. Sinha, M. Rouhi, T. N. Vizard, A. P. Sage, D. Martin, D. T. Ward, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells Cardiovasc Res, February 1, 2009; 81(2): 260 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Nemeth Anabolic Therapy for Osteoporosis: Calcilytics IBMS BoneKEy, June 1, 2008; 5(6): 196 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lomonte, L. Vernaglione, D. Chimienti, A. Bruno, S. Cocola, A. Teutonico, F. Cazzato, and C. Basile Does Vitamin D Receptor and Calcium Receptor Activation Therapy Play a Role in the Histopathologic Alterations of Parathyroid Glands in Refractory Uremic Hyperparathyroidism? Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 794 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Villanueva, C. Cespedes, A. A. Gonzalez, E. Roessler, and C. P. Vio Inhibition of bFGF-receptor type 2 increases kidney damage and suppresses nephrogenic protein expression after ischemic acute renal failure Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R819 - R828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Carrera Foreword NDT Plus, January 1, 2008; 1(suppl_1): i1 - i1. [Full Text] [PDF]
|
|
|
|
|
|
J. Frazao and M. Rodriguez Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy NDT Plus, January 1, 2008; 1(suppl_1): i12 - i17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. M. de Francisco and F. Carrera A New Paradigm for the Treatment of Secondary Hyperparathyroidism NDT Plus, January 1, 2008; 1(suppl_1): i24 - i28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Felsenfeld, M. Rodriguez, and E. Aguilera-Tejero Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1283 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Villanueva, C. Cespedes, A. A. Gonzalez, C. P. Vio, and V. Velarde Effect of ischemic acute renal damage on the expression of COX-2 and oxidative stress-related elements in rat kidney Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1364 - F1371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Villanueva, C. Cespedes, A. Gonzalez, and C. P. Vio bFGF induces an earlier expression of nephrogenic proteins after ischemic acute renal failure Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1677 - R1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Villanueva, C. Cespedes, and C. P. Vio Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2006; 290(4): R861 - R870. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
